Q1 FY27 results and CEO transition at Makers Labs
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts less than Nifty Microcap 250 and 3.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Makers Laboratories Q1 FY27 results (quarter ended June 30, 2026): Consolidated revenue rose 19.6% YoY to Rs 42.77 crores, PAT after non-controlling interest up 150% at Rs 1.09 crores (EPS Rs 1.85). Standalone in loss at Rs 1.07 crores (EPS minus Rs 1.82), wider than Rs 0.96 crores loss in Q1 FY26. CEO Saahil Parikh ends Whole-time Director term on August 10, 2026, continues as Non-Executive Director. Auditor issued unmodified review report.
Consolidated profitability improved sharply but standalone business still loss-making. CEO transition to non-executive role is a notable leadership change.